Physicians' Group Defies Patent Law
To Bring AIDS Drugs to South Africa
By MARK SCHOOFS
Staff Reporter of THE WALL STREET JOURNAL
Doctors Without Borders, the Nobel-Prize
winning humanitarian group, has
defied South African patent law by importing inexpensive generic AIDS
drugs manufactured in Brazil for use in a township clinic outside of
The group, joined by local AIDS activists
in Johannesburg, called on the
South African government Tuesday to open the way for much wider use of
generic drugs in that AIDS-ravaged nation.
By importing the cheaper generic drugs,
"we could be sued for patent
infringement," acknowledged Toby Kasper, a spokesman for Doctors Without
Borders. But noting that the Brazilian imports cost about half the price
of the same medicines made by Western pharmaceutical companies, he
added, "We are not going to stand for a situation where we would be able
to treat twice as many patients as we could by using only patented
drugs. As medical professionals, it is our obligation to put the lives
of our patients first."
About 50 patients, all in the Khayelitsha
township outside of Capetown,
have been taking the Brazilian generic medicines for about one month.
But Doctors Without Borders, better known by its French acronym MSF,
announced the importation only Tuesday at a news conference in Johannesburg.
For MSF and AIDS activists, the Brazilian
drugs marks the latest move in
a protracted campaign to make life-prolonging medications accessible in
poor countries, where AIDS and other epidemics take their greatest toll.
Under public pressure, large pharmaceutical
companies such as
Bristol-Myers Squibb Co. and Merck & Co., have steadily dropped prices
in recent years, only to be undercut by generics from India, Thailand
The two companies that hold patents on the
medicines MSF imported from
Brazil -- GlaxoSmithKline PLC and Boehringer Ingelheim GmbH -- said they
are observing the situation but didn't have immediate plans to take
legal action, which would almost certainly bring down a hail of bad
publicity. "You don't tilt against windmills," said Kevin McKenna, a
spokesman for Boehringer Ingelheim South Africa.
Peter Moore, who runs GSK's South Africa
office, said he was surprised
at MSF's action because Glaxo has entered into an agreement with a South
African generics producer, Aspen Pharmacare Ltd., to manufacture some of
GSK's AIDS drugs. Aspen's generics, however, aren't yet available,
because the company is still in the process of obtaining South African
regulatory approval for such drugs.
As for Boehringer, it offers its AIDS drug
nevirapine in South Africa
for a discounted price of about $1.06 a day. The Brazilian manufacturer,
FarManguinhos, sold the drug to MSF for about 59 cents a day. "Maybe --
maybe -- we can't compete with Brazil," said Mr. McKenna of Boehringer.
He said that his company couldn't sell nevirapine, which it markets
under the name Viramune, for much less than its current price. But he
added that the company would continue its charitable program of offering
the drug free of charge for use in pregnant women, where the drug
slashes the chance of transmitting the AIDS virus to the baby.
In its latest action, MSF is aiming only
part of its fire at
multinational pharmaceutical companies. The activists are also targeting
South Africa's government, which is widely perceived to be obstructing
the use of AIDS drugs, called antiretrovirals.
The South African Department of Health responded
to MSF's action by
saying it would dispatch investigators to see whether MSF is in
compliance with the country's medical regulatory rules. If MSF is found
to have violated the law, the imported drugs "will be confiscated," said
department of health spokesman Sibani Mngadi. However, MSF received a
formal authorization from the South African equivalent of the U.S. Food
and Drug Administration, the Medicines Control Council, to use the drugs
in a research program. MSF said it also received a customs waiver
allowing the drugs to be imported and stated that it would welcome a
visit by health department investigators.
The response of the government appears certain
to intensify the
stand-off between it and AIDS activists. Against overwhelming scientific
evidence, President Thabo Mbeki has questioned whether HIV actually
causes AIDS, and recently he has gone against his country's own
public-health authorities and questioned whether AIDS is really the
leading cause of death in South Africa. The South African Department of
Health estimates that 4.7 million South Africans, or about a quarter of
the country's adults, are infected with HIV.
Mr. Mbeki has also questioned the safety
and efficacy of the AIDS drug
cocktails. AIDS doctors and activists recently took the South African
government to court to force it to make the drugs available to pregnant
mothers, to prevent the transmission of the virus to their babies. The
government lost that case, but has appealed.
The government's increasingly isolated stand
on AIDS has brought intense
criticism from within the country. The Congress of South African Trade
Unions, the nation's largest labor organization, participated in
yesterday's MSF news conference. COSATU has been especially critical of
the government, because it wants its many infected members to be able to
Increasingly, ordinary South Africans are
demanding access to AIDS
medicines, creating a potential rift between the ruling African National
Congress, which overturned apartheid, and the country's majority
population of blacks, who are most heavily affected by the AIDS
epidemic. Twenty-five-year-old Matthew Damane was sick with AIDS last
June, when he entered the MSF program. Now he is working as an AIDS
counselor, and was one of four activists to visit Brazil and bring back
the generic medicines. "I want everyone who has HIV to be treated," he said.
Write to Mark Schoofs at email@example.com
> Health GAP and ACT UP in the United
States are proud to support this
> brave act in South Africa.
> 29 January 2002
> TAC AND MSF IMPORT GENERIC ANTIRETROVIRALS FROM BRAZIL IN DEFIANCE OF
> PATENT ABUSE
> Joint Press Release of Médecins Sans Frontières (MSF), Treatment Action
> Campaign (TAC), and Oxfam
> * Zackie Achmat: (27) 83 467 1152 or (27) (21) 788 5058
> * Mark Heywood: (27) (11) 717 8634
> Generic AIDS Drugs Offer New Lease on Life to South Africans
> Importation of generics cuts price in half
> 29 January 2002, Johannesburg - Yesterday, three members of the Treatment
> Action Campaign, (TAC) returned to South Africa from Brazil carrying
> generic drugs manufactured for use in an AIDS treatment program in
> Khayelitsha. At a press conference today, TAC and MSF explained that the
> drugs carried from Brazil were the second shipment of Brazilian drugs and
> that as of today more than 50 people are already taking the Brazilian
> medicines in Khayelitsha.
> To guarantee the quality of these drugs, an authorisation from the
> Medicines Control Council (MCC), the South African drug regulatory
> authority, was obtained prior to their use.
> "Last week in Brazil we saw what happens when a government decides to
> tackle HIV/AIDS. The Brazilians' decision to offer universal access to
> antiretroviral therapy even in the poorest areas of the country is keeping
> tens of thousands of people alive," said Zackie Achmat of the Treatment
> Action Campaign. "Central to the success of Brazil's AIDS programme is
> their willingness to do anything necessary to source the lowest cost
> quality ARVS. The South African government should pursue compulsory
> licensing to ensure that generic antiretrovirals can be produced and/or
> imported in South Africa."
> At a press conference today, the NGOs said that the court victory of the
> South African government against multinational pharmaceutical companies
> had opened the door to improved access to affordable medicines. "The
> South African government may need international financial help to provide
> treatment, but these needs will be dramatically reduced if the government
> takes steps to use the most affordable drugs available on the worldwide
> market, as the multinational pharmaceutical companies are still charging
> exorbitant prices for these drugs," said Dan Mullins of Oxfam.
> Despite the national government's refusal to provide antiretroviral
> treatment, three clinics run by Médecins Sans Frontières (MSF) within the
> government primary health care centres offer a comprehensive package of
> services to people living with HIV/AIDS, including antiretroviral therapy.
> This project is part of an agreement between MSF and the government of the
> Western Cape, signed two years ago with the express intent to test the
> feasibility of generic antiretroviral therapy. These clinics, located in
> Khayelitsha, a sprawling township of 500,000 people outside Cape Town,
> were opened in April 2000 and have provided treatment for opportunistic
> infections for over 2,300 people living with HIV/AIDS.
> In May 2001, combination antiretroviral therapy was introduced for a group
> of people in advanced stages of AIDS. To date, 85 people have received
> antiretroviral therapy and 50 of these are receiving Brazilian medicines.
> Using generic antiretrovirals offers the possibility of treating twice the
> number of people with the same amount of money.
> "I have personally benefited from the MSF antiretroviral programme, and I
> have gone to Brazil to bring back generics so that more people like me can
> have access to these medicines," said Matthew Damane, a person living with
> AIDS who is receiving antiretroviral therapy as part of the MSF programme
> in Khayelitsha. "The government should publicly accept the effectiveness
> of these medicines and make them available to people with AIDS in South
> "Our project shows that antiretroviral therapy is feasible in a
> resource-poor setting, contrary to those who insist that poor Africans are
> not able to successfully take these drugs. Patients who were critically
> ill are now returning to their normal lives," said Dr. Eric Goemaere of
> MSF South Africa. "We have seen firsthand that these drugs can be used
> safely and effectively here in South Africa. As medical professionals, it
> is our duty to offer these benefits to as many patients as possible."
> Similar initiatives are springing up elsewhere around the country as
> medical staff become increasingly frustrated by the lack of action from
> the national government. Nonetheless, the price of medicines continues to
> be a critical problem.
> MSF has signed agreements with the Brazilian Ministry of Health (MoH) and
> Fiocruz, a public research body funded by the Brazilian government. The
> former established a cooperative agreement involving technical
> collaboration on the response to HIV/AIDS, so that MSF and the Brazilian
> MoH can collaborate to improve the delivery of treatment in resource-poor
> settings. The agreement with Fiocruz allows MSF to purchase antiretroviral
> drugs produced by FarManguinhos, the Brazilian national pharmaceutical
> producer, which is part of Fiocruz.
> An innovative aspect of this arrangement is that the money MSF pays will
> go directly into research and development for AIDS and neglected diseases
> such as sleeping sickness, Chagas Disease and malaria (all diseases for
> which current treatment options are inadequate).
> MSF is currently using the antiretroviral drugs AZT, 3TC, co-formulated
> AZT/3TC, and nevirapine produced by FarManguinhos. By using these drugs
> the price per patient per day falls from US$3.20 to US$1.55.
> In 1996, in response to pressure from civil society, the Brazilian
> government began providing free access to antiretroviral therapy to people
> with HIV/AIDS. This policy has allowed more than 100,000 people to receive
> antiretroviral therapy and reduced AIDS-related mortality by more than
> 50%. Between 1997 and 2000, antiretroviral treatment has saved the
> Brazilian government $677 million on hospitalisations averted and
> treatment for opportunistic infections averted.
> South Africa could launch a similar programme. To do so, the government
> needs to have access to the lowest cost medicines, whether they come from
> multinational pharmaceutical companies or from generic producers. This
> means both taking advantage of offers from multinational companies and
> being willing to seek compulsory licenses. These licenses can be used to
> produce these drugs locally or import them and are an important way to
> stimulate competition, which is a powerful tool to reduce prices.
> Additional background information is available on the websites of MSF and
> TAC: www.tac.org.za and www.accessmed-msf.org
> COSATU Statement on the Importation of Generic Antiretrovirals from Brazil
> The Congress of South African Trade Unions (COSATU) and
> the Treatment Action Campaign (TAC) have returned from a
> visit to Brazil. The delegation included Joyce Pekane, Second
> Deputy President of COSATU, Zackie Achmat, Chairperson of
> TAC, Nomandla Yako, and Matthew Demane, a person who is
> living with AIDS and currently being treated with anti-retroviral
> The delegates, hosted by Médecins sans Frontières (MSF),
> looked at Brazilian HIV/AIDS treatment programmes, visited
> factories which manufacture generic anti-retroviral medicines and
> met government officials and people living with AIDS. The
> Brazilian government has formally offered the South African
> government help in fighting HIV/AIDS.
> On their return the delegates brought back a batch of generic
> anti-retroviral medicines for use by MSF in a treatment
> programme in Khayelitsha. The Medicines Control Council
> (MCC), having studied the safety of these medicines, has given a
> Section 21 exemption which allows for them to be imported and
> used by MSF.
> The equivalent drugs are in fact available in South Africa,
> produced by GlaxoSmithKlein (GSK) and Boehringer
> Ingelheim. But they cost approximately R1000 per month
> compared to the cost of R450 for the medicines being brought
> from Brazil.
> The importation of these drugs for use under strict conditions by
> MSF has been approved by the MCC. We are aware that it
> may infringe patent rights. However, we believe that faced by an
> emergency caused by AIDS, and in face of overwhelming
> support for the government's view that patent rights should not
> be used to deny people access to life-saving medicines that this
> importation is in line with government and international policy.
> COSATU, TAC and MSF stand by their belief that the
> government and society as a whole must get anti-retroviral
> medicines to the people who need then as quickly and
> cheaply as possible and must not let the vested interests of multi-
> national pharmaceutical manufacturers to prevent this.
> This is why these medicines are being brought in. The MSF
> programme in Khayelitsha is already improving the lives of over
> 80 people. With affordable medicines many more people could
> be reached, not only in the Western Cape but throughout SA.
> Patrick Craven and Moloto Mothapo
> Acting COSATU Spokespersons
> 011 339 4911 0r 082 821 7456
> Questions and Answers about TAC and MSF Importing Generic Medicines from
> 1.What medicines have been imported from Brazil?
> TAC and MSF have imported generic antiretroviral medicines from Brazil.
> The scientific names for these medicines are Zidovudine (AZT), Lamivudine
> and Nevirapine. For part of the imported batch, AZT and Lamivudine are
> combined together into one capsule.
> 2.What are these medicines used for?
> They stop HIV from reproducing in the human body. This allows the immune
> systems of people who have HIV/AIDS to get better (reconstitute). These
> medicines have been shown to help people with HIV/AIDS to live longer,
> healthier lives.
> 3.Have TAC and MSF broken the law?
> There are patents on these medicines in South Africa. TAC and MSF have
> committed an act of defiance. By importing them from Brazil, TAC and MSF
> have infringed the patents. The constitution, which is the highest law in
> South Africa, protects the rights to life and dignity. By bringing in
> these medicines, TAC and MSF believe they are upholding these rights. Note
> that patent infringement is a civil matter, not a criminal one.
> 4.Why did TAC and MSF do this?
> There are patents on these medicines in South Africa. This means that
> there is no competition on these drugs in South Africa. They are therefore
> much too expensive. By importing these drugs from Brazil in breach of the
> country's patent law at much lower prices, TAC and MSF are challenging
> both the South African government and the pharmaceutical industry. The
> government is being challenged to pursue voluntary and compulsory licenses
> (see next question) from the patent-holding pharmaceutical companies. The
> pharmaceutical companies are being challenged to offer non-exclusive
> voluntary licenses (see next question) available on their essential
> 5.What are compulsory licenses and voluntary licenses on medicines?
> A company that holds a patent on a medicine can allow pharmaceutical
> manufacturers to make this medicine. If they do this, they are giving
> voluntary licenses to other pharmaceutical manufacturers. If a
> pharmaceutical company refuses to give voluntary licenses to other
> manufacturers, a court can order that a compulsory license be issued,
> giving other manufacturers the opportunity to produce the medicine. It is
> compulsory because the patent-holder does not have a choice. It must allow
> companies to manufacture the medicine in competition to it. A court will
> only issue a compulsory license if there is a good legal reason to do so.
> Furthermore, it is necessary to first ask the pharmaceutical company to
> issue voluntary licenses. TAC and MSF want the government to ask the
> pharmaceutical companies for voluntary licenses. If they refuse to adhere
> to the government request, the government must then pursue compulsory
> licenses using the courts.
> 6.What is meant by a non-exclusive voluntary license?
> It is seldom that pharmaceutical companies issue voluntary licenses. When
> they occasionally do, they often limit the voluntary licenses to a few
> companies (usually only one) of their choice; i.e, they make the license
> available on an exclusive basis. A non-exclusive license, means that any
> company may manufacture them.
> 7.Why do TAC and MSF want non-exclusive compulsory and voluntary licenses
> on essential medicines?
> This will create competition among the drug companies and ensure that
> their prices drop. Exclusive licenses are not good enough, because
> allowing more manufacturers into the market creates more competition and
> therefore lower prices.
> 8.What are the respective roles of TAC and MSF in this defiance campaign?
> The organisations planned this together. MSF paid for the medicines. TAC
> volunteers, Zackie Achmat, Matthew Damane and Nomandla Yako, have brought
> the medicines into the country. Both organisations will share any legal
> liability that may arise from this action.
> 9.What role do Cosatu and Oxfam have in this campaign?
> Cosatu and Oxfam support what TAC and MSF have done. Furthermore, Cosatu
> secretariat member, Joyce Pikane, accompanied the TAC volunteers on their
> mission to Brazil.
> 10.Which Brazilian company manufactured and sold these medicines to MSF?
> Farmanguinhos, which is owned and managed by the Brazilian government,
> manufactured and sold these medicines to MSF Brazil. MSF Brazil has
> donated these drugs to the MSF antiretroviral pilot programme in
> 11.Are these generic medicines of the same quality as the patented
> versions sold in South Africa?
> Tests have been conducted on them which show that from a medical point of
> view, they are identical in quality and effect to the patented versions
> sold in South Africa. Furthermore, the Medicine Control Council has
> granted MSF what are known as section 21 exemptions to use these
> medicines. The section 21 exemptions would not have been granted if the
> medicines were not considered to be safe and effective. No medicine can
> be used in South Africa (whether registered or exempted from the
> registration procedures) without the MCC's approval. Such approval is
> only granted if the MCC is satisfied that the medicines are safe and
> 12.President Mbeki says these drugs (generic or patented) are toxic. What
> is TAC's response?
> Nearly all medicines have side-effects, even paracetamol (which most
> people know by the brand-name Panado). However the benefits of
> antiretrovirals far outweigh the side-effects. Of course, people on
> antiretrovirals must be monitored regularly by their doctor or clinic.
> When this is done correctly, antiretrovirals are safe and effective. In
> Brazil, these medicines have been responsible for reducing the rate at
> which people with HIV die by 50%. In rich countries in Europe and North
> America, the rate at which people with HIV die has been reduced by over
> 70%. People who need antiretrovirals and do not have access to them
> usually die prematurely.
> 13.If compulsory licenses are issued on these drugs, how can South
> Africans be sure that generic versions will be safe to use?
> No drug can be used in South Africa without the Medicine Control Council's
> permission. There role is to ensure that medicines are safe and effective.
> Any generic medicine has to be registered with the Medicine Control
> Council who will check that it is safe and effective.
> 14.Who holds the patents on AZT, Lamivudine and Nevirapine in South
> Boehringer Ingelheim holds the patent on Nevirapine. GlaxoSmithKline holds
> the patents on AZT and Lamivudine.
> 15.What are the price differences between the medicines bought in Brazil
> and the ones sold here?
> GlaxoSmithKline has offered AZT and Lamivudine (in combination) to the
> South African government at US$2 per day (at the current exchange rate
> this is about R22.80 per day). Farmanguinhos sell it to MSF at US$0.96
> (about R10.94 ) per day. Boehringer Ingelheim sell Nevirapine for US$1.19
> (about R11.63) per day in South Africa. Farmanguinhos sell it to MSF at
> US$0.59 (about R6.76) per day.
> 16.Why are these medicines not patented in Brazil?
> Brazil's patent laws only started applying to pharmaceutical products in
> 1997. Therefore, all drugs developed before then are not patented in
> Brazil. This includes AZT, Lamivudine and Nevirapine. For more on the
> situation on Brazil, see TAC's fact sheet on the Brazilian response to
> 17.TAC has imported medicines as part of a defiance campaign before. What
> is different this time?
> TAC continues to import generic fluconazole from Biolab in Thailand in
> defiance of Pfizer's patent. This campaign has saved and improved the
> lives of about a thousand people. However, fluconazole is a medicine used
> to treat opportunistic infections that occur in people with HIV/AIDS. The
> antiretrovirals imported from Brazil are used to control HIV itself so
> that it is less likely for infected people to get opportunistic
> infections. Eventually, nearly everyone with HIV needs antiretrovirals to
> continue living.
> 18.Why have these three antiretroviral medicines been chosen?
> MSF is conducting a pilot treatment programme in Khayelitsha. The standard
> first-line regimen for their patients is AZT, Lamivudine and Nevirapine or
> AZT, Lamivudine and Efavirenz. By buying the generic versions from Brazil,
> MSF can substantially increase the number of people on this programme
> (currently 85 people).
> 19.DDI and D4T are cheaper than AZT and Lamivudine. Why does MSF not use
> these drugs instead?
> Firstly, the AZT and Lamivudine from Brazil are cheaper than the versions
> of ddI and d4T available in South Africa. Furthermore, for most people,
> AZT and Lamivudine are a better option to begin with than ddI and d4T.
> 20.As with fluconazole, will these medicines be made generally available
> to the public through doctors?
> NO! Antiretroviral medicines are expensive and require more complex
> logistics to administer and monitor than fluconazole. These drugs are
> being imported only for use in the MSF programme in Khayelitsha.
> Unfortunately, they cannot be offered to anyone not on the programme.
> Ultimately, this enormous task must fall upon the state and the private
> sector as a whole. It can only happen on a large scale once the government
> adopts a national HIV/AIDS treatment and prevention plan.
> 21.GlaxoSmithKline has given Aspen Phamacare a voluntary license to
> produce AZT and Lamivudine. Why is this not good enough? Why did MSF and
> TAC not get the drugs from Aspen?
> The license is exclusive and it has draconian conditions attached to it.
> Aspen may only sell their drugs to NGOs and the public sector. TAC and MSF
> are demanding that non-exclusive voluntary licenses be made available for
> sale to both the public and private sectors. Furthermore, Aspen's drugs
> are not yet ready and they have indicated that their price will be higher
> than Farmanguinhos's price.
> 22.Boehringer Ingelheim have offered Nevirapine for free. How can the
> price possibly get lower than that?
> The company has offered Nevirapine for free only for the use of
> mother-to-child transmission prevention in the public sector. It is not
> offered for free as part of an antiretroviral treatment programme. TAC has
> calculated that Boehringer's donation of Nevirapine amounts to
> approximately R1.5 million per year (using Boehringer's price) if a
> country-wide mother-to-child transmission prevention programme is fully
> implemented. Putting just 355 people with AIDS on Nevirapine for a year
> exceeds the donation amount in revenue. The donation is double-edged and
> aimed at taking attention off the area where the real costs for South
> Africa lie: treating people with HIV/AIDS.
> 23.The pharmaceutical companies say that compulsory licenses are property
> theft and that if they are issued South Africa will be doing what Mugabe
> has done in Zimbabwe. What is TAC's response?
> Firstly, a compulsory license is something allowed by South African and
> international law, after due process. Secondly, when a compulsory license
> is issued, the generic manufacturers have to compensate the patent-holder.
> TAC has asked that generic manufacturers pay a 5% royalty fee to the
> patent-holders. The analogy with Zimbabwe is ridiculous. In Zimbabwe, the
> law has been ignored and perverted. Even the forcibly evicted farmers in
> Zimbabwe do not deny that there is a need for land reform. However, what
> is wrong in Zimbabwe is the means that have been used to carry out
> Mugabe's so-called land reform programme. While compulsory licenses on
> medicines will save lives, Mugabe's actions are endangering lives.
> 24.Would issuing compulsory licenses put the South African government in
> breach of its international obligations?
> South Africa is a signatory to the World Trade Organisation Trade Related
> Aspects of Intellectual Property Rights (TRIPs) agreement. This agreement
> sets out the minimum standards of intellectual property protection that
> countries must abide by. This agreement makes provision for compulsory
> licenses. Furthermore, in a recent meeting of the World Trade
> Organisation's members in Doha, Quatar, it was agreed that TRIPs should
> not stand in the way of a country's health concerns. The South African
> government can pursue compulsory licenses without breaching its
> international obligations and without scaring off foreign investors (if
> the process is managed correctly).
> 25.What is TAC's position on local production of generic antiretrovirals?
> Local production is essential for a number of reasons. It will (a) create
> more competition, (b) insulate, to some extent, the prices of
> antiretrovirals against the depreciation of the rand and (c) create jobs.
> Both local production and importation of antiretrovirals will be essential
> to meet the country's (and the SADC region's) treatment needs.
> Antiretrovirals need to be taken for life. It is therefore crucial that
> the supply of these medicines be sustainable. The best way of guaranteeing
> this is via competition between producers, including local ones.
Message from the Brazilian Ministry of Health
With regards to the reports recently published in the international press
concerning the alleged exports of Brazilian-made antiretroviral drugs to
South Africa, the Brazilian Ministry of Health wishes to make it clear that
Brazil has definitely no policy of exporting generic Aids drugs. Brazil's
production of such medicines is aimed solely at meeting the needs of the
105,000 Brazilians who receive this medication free of charge from the
Government. The drugs which are being received by the Brazil Section of the
Non Governmental Organisation Médécins sans Fontières form part of a
technical cooperation agreement signed between the Oswaldo Cruz Foundation
(FIOCRUZ) of the Brazilian Ministry of Health and the Brazil Section of
Médécins sans Fontières. The drugs at issue were acquired from the
Farmanguinhos laboratory, which operates under the auspices of the FIOCRUZ,
at cost price and as part of the aforementioned technical cooperation
agreement within the context of the development of new molecules partially
funded by MSF, and of improving access and adhesion to care and treatment in
MSF pilot projects. The agreement includes provision for the supply of small
quantities of antiretroviral drugs produced in Brazil, to be used in the
course of pilot projects by that particular Non Governmental Organisation.
use back button on browser to return